Biotech Values

[microcapfun]

Cordaptive Causes Less Flushing, More Side effects Than Niaspan

Incyte's HM74a agonist program sounds interesting. I think they are interested in elevating HDL cholesterol in addition to the diabetes application discussed below.

>>Incyte will also introduce its HM74a agonist program. HM74a is the receptor to which niacin binds and activates, resulting in a reduction in plasma free fatty acid levels. High free fatty acid levels have been shown to cause insulin resistance and hyperglycemia, and while substantial clinical data support the potential for HM74a agonism to provide therapeutic benefit in type 2 diabetes, the currently available HM74a agonist - niacin - in its various formulations is not used primarily because its short duration of activity does not allow for effective and sustained lowering of free fatty acid levels. In addition, niacin causes cutaneous flushing which is often poorly tolerated. Our lead HM74a agonist, INCB19602, has now completed a single-dose Phase I trial, in which low and well tolerated doses dramatically reduced free fatty acid levels in an effective and sustained fashion and did not cause any cutaneous flushing. Provided the compound successfully completes the ongoing multiple-dose Phase I trial, Incyte plans to initiate a Phase IIa trial in type 2 diabetic patients in the first half of 2008.<<

http://investor.incyte.com/phoenix.zhtml?c=69764&p=IROL-NewsText&t=Regular&id=1093195&

>>For INCB19602, our recently announced lead HM74a agonist that we
intend to develop as a treatment for type 2 diabetes, we completed a
single-dose Phase I trial in healthy volunteers in which low and well
tolerated doses dramatically reduced free fatty acid levels and did
not cause any of the cutaneous flushing that is seen with the
currently available HM74a agonist, niacin <<

http://investor.incyte.com/phoenix.zhtml?c=69764&p=IROL-NewsText&t=Regular&id=1108185&

micro